Drug intelligence / Profile preview

20kPEG-AM

Development stage: Preclinical
Modality: Peptides
Administration: Subcutaneous

Overview

20kPEG-AM is a polyethylene glycol (PEG)ylated form of human adrenomedullin (AM), a hypotensive peptide known for its anti-colitis activity. It is synthesized through the conjugation of PEG-AM (1–15) and AM (15–52). This modified peptide functions by stimulating cyclic adenosine monophosphate (cAMP) production in cells that stably express the type 1 AM receptor. Preclinical studies in murine models of colitis have shown that subcutaneous administration of 20kPEG-AM significantly reduces total inflammation scores, indicating its potential as a therapeutic candidate for inflammatory bowel diseases. The drug exhibits a half-life of 7.4 hours following subcutaneous administration in mice.

Other names: 20 kDa PEG-AMPEGylated Adrenomedullin

Targets

CALCRL (Adrenomedullin Receptor)

Beyond the preview

Go deeper on 20kPEG-AM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 20kPEG-AM.

Explore the full profile